Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CPB2 | Q96IY4 | 19/20 | 0.44 |
| ▸ | CPB1 | P15086 | 1/20 | 0.44 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.36 |
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.36 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12255867 | 1.00 | CPB2 (0.44) | CPB2CPB1HDAC1HDAC8HDAC6 | |
| Hydrochloric Acid SCHEMBL2235438 | 0.99 | CPB2 (0.43) | CPB2CPB1HDAC1HDAC8HDAC6 | |
| Hydrochloric Acid SCHEMBL2235430 | 0.99 | CPB2 (0.43) | CPB2CPB1HDAC1HDAC8HDAC6 | |
| SCHEMBL12255810 | 0.87 | CPB2 (0.42) | CPB2CPB1 | |
| SCHEMBL12255864 | 0.87 | CPB2 (0.42) | CPB2CPB1 | |
| SCHEMBL10293895 | 0.86 | CPB2 (0.44) | CPB2 | |
| Hydrochloric Acid SCHEMBL2233595 | 0.86 | CPB2 (0.41) | CPB2CPB1 | |
| Hydrochloric Acid SCHEMBL2233954 | 0.86 | CPB2 (0.41) | CPB2CPB1 | |
| Hydrochloric Acid SCHEMBL2236186 | 0.86 | CPB2 (0.44) | CPB2 | |
| SCHEMBL2238257 | 0.85 | CPB2 (0.42) | CPB2CPB1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110213143-A1 | COMPOUND HAVING TAFIA INHIBITORY ACTIVITY | TAISHO PHARMACEUTICAL CO., LTD. (JP) | 2011-09-01 | — | — | US | disclosed |
| US-20110213143-A1 | COMPOUND HAVING TAFIA INHIBITORY ACTIVITY | TAISHO PHARMACEUTICAL CO., LTD. (JP) | 2011-09-01 | — | — | US | disclosed |
| EP-2361910-A1 | COMPOUND HAVING TAFIA INHIBITORY ACTIVITY | Taisho Pharmaceutical Co., Ltd. (JP) | 2011-08-31 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110213143-A1 | COMPOUND HAVING TAFIA INHIBITORY ACTIVITY | TAF1, TAF5, TAF11 | CPB2 56/4885CPB1 50/4885HDAC1 238/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.